SLC5A2 and type 2 diabetes mellitus: One of the first meta-analyses investigating the antihypertensive effect of SGLT2 inhibitors specifically in T2DM patients showed that they exerted a reduction in SBP and diastolic BP (DBP) by 4 (95% CI: −4.4 to −3.5) mmHg and 1.6 (95% CI: −1.9 to −1.3) mmHg, respectively.